Developments of Glucagon Like Peptide-1 (GLP-1) and Long-acting Analogs in Clinical and Preclinical Studies for Treatment of Type 2 Diabetes

Author(s): Yazhuo Li, Lida Tang, Min Gong

Journal Name: Current Pharmaceutical Biotechnology

Volume 14 , Issue 9 , 2013

Become EABM
Become Reviewer


The outstanding physiological functions of glucagon-like peptide-1 make it a promising drug candidate for blood glucose regulation in type 2 diabetes. However, the short half-life of GLP-1 limited its widely clinical utility due to the rapid degradation by dipeptidyl peptidase IV (DPP-IV) and renal clearance. Therefore, stabilisation of glucagon-like peptide-1 is critical for the use of this peptide in drug development. Scientists in pharmaceutical companies have contributed in years to obtain long-acting or sustained GLP-1 derivatives which are reviewed in this report.

Keywords: GLP-1, Long-acting analogs, Type 2 diabetes.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 22 January, 2014
Page: [835 - 841]
Pages: 7
DOI: 10.2174/1389201014666131227120546
Price: $65

Article Metrics

PDF: 28